PhRMA’s Loss in Drug Pricing Suit Eased by Focus on Jurisdiction

Feb. 13, 2024, 9:49 PM UTC

The leading pharmaceutical industry group was dealt a blow with the dismissal of its lawsuit challenging a government price-setting program, but the decision’s focus on jurisdictional issues rather than the merits of the arguments mutes the federal government’s victory.

The Pharmaceutical Research and Manufacturers of America, joined by the National Infusion Center Association and the Global Colon Cancer Association, faced rejection Monday from the US District Court for the Western District of Texas when Judge David Alan Ezra ruled the court lacks jurisdiction to handle the case.

The challenge is the first to be thrown out among the cluster of ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.